- Home
- SCNX vs ITRM Comparison
SCNX vs ITRM Comparison
Compare SCNX & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCNX | ITRM |
|---|---|---|
| Founded | 2010 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.8M | 24.3M |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | SCNX | ITRM |
|---|---|---|
| Price | $0.51 | $0.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 1.7M | 704.9K |
| Earning Date | 11-13-2025 | 02-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $653,391.00 | $390,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $193.01 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 207.88 | N/A |
| 52 Week Low | $0.46 | $0.30 |
| 52 Week High | $7.69 | $2.10 |
Technical Indicators
Market Signals| Indicator | SCNX | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 41.93 | 25.10 |
| Support Level | $0.49 | $0.44 |
| Resistance Level | $0.60 | $0.37 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 6.82 | 1.74 |
Price Performance
Historical ComparisonAbout SCNX Scienture Holdings Inc.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.